Global Hepatocellular Carcinoma Drugs Market Research Report 2023

HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.

The global Hepatocellular Carcinoma Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

The incidence rate of hepatic cancer such as intrahepatic bile duct cancer in U.S. was approximately 39,230 during 2017. The risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to keep up the growth of global hepatocellular carcinoma treatment market. However, side effects associated with the chemotherapy, high cost of treatment are some of the major restraints limiting the growth of global hepatocellular carcinoma treatment market.

This report aims to provide a comprehensive presentation of the global market for Hepatocellular Carcinoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatocellular Carcinoma Drugs.

The Hepatocellular Carcinoma Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Hepatocellular Carcinoma Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hepatocellular Carcinoma Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Brachytherapy

1.2.3 Chemotherapy

1.2.4 Local Ablation Therapy

1.3 Market by Application

1.3.1 Global Hepatocellular Carcinoma Drugs Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Cancer Rehabilitation Centers

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Hepatocellular Carcinoma Drugs Market Perspective (2018-2029)

2.2 Hepatocellular Carcinoma Drugs Growth Trends by Region

2.2.1 Global Hepatocellular Carcinoma Drugs Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Hepatocellular Carcinoma Drugs Historic Market Size by Region (2018-2023)

2.2.3 Hepatocellular Carcinoma Drugs Forecasted Market Size by Region (2024-2029)

2.3 Hepatocellular Carcinoma Drugs Market Dynamics

2.3.1 Hepatocellular Carcinoma Drugs Industry Trends

2.3.2 Hepatocellular Carcinoma Drugs Market Drivers

2.3.3 Hepatocellular Carcinoma Drugs Market Challenges

2.3.4 Hepatocellular Carcinoma Drugs Market Restraints

3.1 Global Top Hepatocellular Carcinoma Drugs Players by Revenue

3.1.1 Global Top Hepatocellular Carcinoma Drugs Players by Revenue (2018-2023)

3.1.2 Global Hepatocellular Carcinoma Drugs Revenue Market Share by Players (2018-2023)

3.2 Global Hepatocellular Carcinoma Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Hepatocellular Carcinoma Drugs Revenue

3.4 Global Hepatocellular Carcinoma Drugs Market Concentration Ratio

3.4.1 Global Hepatocellular Carcinoma Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hepatocellular Carcinoma Drugs Revenue in 2022

3.5 Hepatocellular Carcinoma Drugs Key Players Head office and Area Served

3.6 Key Players Hepatocellular Carcinoma Drugs Product Solution and Service

3.7 Date of Enter into Hepatocellular Carcinoma Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Type (2018-2023)

4.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Type (2024-2029)

5.1 Global Hepatocellular Carcinoma Drugs Historic Market Size by Application (2018-2023)

5.2 Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Application (2024-2029)

6.1 North America Hepatocellular Carcinoma Drugs Market Size (2018-2029)

6.2 North America Hepatocellular Carcinoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023)

6.4 North America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Hepatocellular Carcinoma Drugs Market Size (2018-2029)

7.2 Europe Hepatocellular Carcinoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023)

7.4 Europe Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size (2018-2029)

8.2 Asia-Pacific Hepatocellular Carcinoma Drugs Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2018-2023)

8.4 Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Hepatocellular Carcinoma Drugs Market Size (2018-2029)

9.2 Latin America Hepatocellular Carcinoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023)

9.4 Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size (2018-2029)

10.2 Middle East & Africa Hepatocellular Carcinoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023)

10.4 Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Bayer

11.1.1 Bayer Company Detail

11.1.2 Bayer Business Overview

11.1.3 Bayer Hepatocellular Carcinoma Drugs Introduction

11.1.4 Bayer Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.1.5 Bayer Recent Development

11.2 Eli Lilly

11.2.1 Eli Lilly Company Detail

11.2.2 Eli Lilly Business Overview

11.2.3 Eli Lilly Hepatocellular Carcinoma Drugs Introduction

11.2.4 Eli Lilly Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.2.5 Eli Lilly Recent Development

11.3 Johnson and Johnson

11.3.1 Johnson and Johnson Company Detail

11.3.2 Johnson and Johnson Business Overview

11.3.3 Johnson and Johnson Hepatocellular Carcinoma Drugs Introduction

11.3.4 Johnson and Johnson Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.3.5 Johnson and Johnson Recent Development

11.4 Pfizer

11.4.1 Pfizer Company Detail

11.4.2 Pfizer Business Overview

11.4.3 Pfizer Hepatocellular Carcinoma Drugs Introduction

11.4.4 Pfizer Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.4.5 Pfizer Recent Development

11.5 Bristol-Myers Squibb

11.5.1 Bristol-Myers Squibb Company Detail

11.5.2 Bristol-Myers Squibb Business Overview

11.5.3 Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Introduction

11.5.4 Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.5.5 Bristol-Myers Squibb Recent Development

11.6 Celgene

11.6.1 Celgene Company Detail

11.6.2 Celgene Business Overview

11.6.3 Celgene Hepatocellular Carcinoma Drugs Introduction

11.6.4 Celgene Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.6.5 Celgene Recent Development

11.7 F. Hoffmann-la Roche

11.7.1 F. Hoffmann-la Roche Company Detail

11.7.2 F. Hoffmann-la Roche Business Overview

11.7.3 F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Introduction

11.7.4 F. Hoffmann-la Roche Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.7.5 F. Hoffmann-la Roche Recent Development

11.8 Gilead

11.8.1 Gilead Company Detail

11.8.2 Gilead Business Overview

11.8.3 Gilead Hepatocellular Carcinoma Drugs Introduction

11.8.4 Gilead Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.8.5 Gilead Recent Development

11.9 GlaxoSmithKline

11.9.1 GlaxoSmithKline Company Detail

11.9.2 GlaxoSmithKline Business Overview

11.9.3 GlaxoSmithKline Hepatocellular Carcinoma Drugs Introduction

11.9.4 GlaxoSmithKline Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.9.5 GlaxoSmithKline Recent Development

11.10 Merck

11.10.1 Merck Company Detail

11.10.2 Merck Business Overview

11.10.3 Merck Hepatocellular Carcinoma Drugs Introduction

11.10.4 Merck Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.10.5 Merck Recent Development

11.11 Novartis

11.11.1 Novartis Company Detail

11.11.2 Novartis Business Overview

11.11.3 Novartis Hepatocellular Carcinoma Drugs Introduction

11.11.4 Novartis Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023)

11.11.5 Novartis Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Hepatocellular Carcinoma Drugs Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Brachytherapy

    Table 3. Key Players of Chemotherapy

    Table 4. Key Players of Local Ablation Therapy

    Table 5. Global Hepatocellular Carcinoma Drugs Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 6. Global Hepatocellular Carcinoma Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Hepatocellular Carcinoma Drugs Market Size by Region (2018-2023) & (US$ Million)

    Table 8. Global Hepatocellular Carcinoma Drugs Market Share by Region (2018-2023)

    Table 9. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 10. Global Hepatocellular Carcinoma Drugs Market Share by Region (2024-2029)

    Table 11. Hepatocellular Carcinoma Drugs Market Trends

    Table 12. Hepatocellular Carcinoma Drugs Market Drivers

    Table 13. Hepatocellular Carcinoma Drugs Market Challenges

    Table 14. Hepatocellular Carcinoma Drugs Market Restraints

    Table 15. Global Hepatocellular Carcinoma Drugs Revenue by Players (2018-2023) & (US$ Million)

    Table 16. Global Hepatocellular Carcinoma Drugs Market Share by Players (2018-2023)

    Table 17. Global Top Hepatocellular Carcinoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Drugs as of 2022)

    Table 18. Ranking of Global Top Hepatocellular Carcinoma Drugs Companies by Revenue (US$ Million) in 2022

    Table 19. Global 5 Largest Players Market Share by Hepatocellular Carcinoma Drugs Revenue (CR5 and HHI) & (2018-2023)

    Table 20. Key Players Headquarters and Area Served

    Table 21. Key Players Hepatocellular Carcinoma Drugs Product Solution and Service

    Table 22. Date of Enter into Hepatocellular Carcinoma Drugs Market

    Table 23. Mergers & Acquisitions, Expansion Plans

    Table 24. Global Hepatocellular Carcinoma Drugs Market Size by Type (2018-2023) & (US$ Million)

    Table 25. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2018-2023)

    Table 26. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 27. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Type (2024-2029)

    Table 28. Global Hepatocellular Carcinoma Drugs Market Size by Application (2018-2023) & (US$ Million)

    Table 29. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2018-2023)

    Table 30. Global Hepatocellular Carcinoma Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 31. Global Hepatocellular Carcinoma Drugs Revenue Market Share by Application (2024-2029)

    Table 32. North America Hepatocellular Carcinoma Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 33. North America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)

    Table 34. North America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)

    Table 35. Europe Hepatocellular Carcinoma Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 36. Europe Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)

    Table 37. Europe Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)

    Table 38. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 39. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2018-2023) & (US$ Million)

    Table 40. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size by Region (2024-2029) & (US$ Million)

    Table 41. Latin America Hepatocellular Carcinoma Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 42. Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)

    Table 43. Latin America Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)

    Table 44. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 45. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2018-2023) & (US$ Million)

    Table 46. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size by Country (2024-2029) & (US$ Million)

    Table 47. Bayer Company Detail

    Table 48. Bayer Business Overview

    Table 49. Bayer Hepatocellular Carcinoma Drugs Product

    Table 50. Bayer Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 51. Bayer Recent Development

    Table 52. Eli Lilly Company Detail

    Table 53. Eli Lilly Business Overview

    Table 54. Eli Lilly Hepatocellular Carcinoma Drugs Product

    Table 55. Eli Lilly Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 56. Eli Lilly Recent Development

    Table 57. Johnson and Johnson Company Detail

    Table 58. Johnson and Johnson Business Overview

    Table 59. Johnson and Johnson Hepatocellular Carcinoma Drugs Product

    Table 60. Johnson and Johnson Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 61. Johnson and Johnson Recent Development

    Table 62. Pfizer Company Detail

    Table 63. Pfizer Business Overview

    Table 64. Pfizer Hepatocellular Carcinoma Drugs Product

    Table 65. Pfizer Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 66. Pfizer Recent Development

    Table 67. Bristol-Myers Squibb Company Detail

    Table 68. Bristol-Myers Squibb Business Overview

    Table 69. Bristol-Myers Squibb Hepatocellular Carcinoma Drugs Product

    Table 70. Bristol-Myers Squibb Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 71. Bristol-Myers Squibb Recent Development

    Table 72. Celgene Company Detail

    Table 73. Celgene Business Overview

    Table 74. Celgene Hepatocellular Carcinoma Drugs Product

    Table 75. Celgene Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 76. Celgene Recent Development

    Table 77. F. Hoffmann-la Roche Company Detail

    Table 78. F. Hoffmann-la Roche Business Overview

    Table 79. F. Hoffmann-la Roche Hepatocellular Carcinoma Drugs Product

    Table 80. F. Hoffmann-la Roche Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 81. F. Hoffmann-la Roche Recent Development

    Table 82. Gilead Company Detail

    Table 83. Gilead Business Overview

    Table 84. Gilead Hepatocellular Carcinoma Drugs Product

    Table 85. Gilead Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 86. Gilead Recent Development

    Table 87. GlaxoSmithKline Company Detail

    Table 88. GlaxoSmithKline Business Overview

    Table 89. GlaxoSmithKline Hepatocellular Carcinoma Drugs Product

    Table 90. GlaxoSmithKline Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 91. GlaxoSmithKline Recent Development

    Table 92. Merck Company Detail

    Table 93. Merck Business Overview

    Table 94. Merck Hepatocellular Carcinoma Drugs Product

    Table 95. Merck Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 96. Merck Recent Development

    Table 97. Novartis Company Detail

    Table 98. Novartis Business Overview

    Table 99. Novartis Hepatocellular Carcinoma Drugs Product

    Table 100. Novartis Revenue in Hepatocellular Carcinoma Drugs Business (2018-2023) & (US$ Million)

    Table 101. Novartis Recent Development

    Table 102. Research Programs/Design for This Report

    Table 103. Key Data Information from Secondary Sources

    Table 104. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Hepatocellular Carcinoma Drugs Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Hepatocellular Carcinoma Drugs Market Share by Type: 2022 VS 2029

    Figure 3. Brachytherapy Features

    Figure 4. Chemotherapy Features

    Figure 5. Local Ablation Therapy Features

    Figure 6. Global Hepatocellular Carcinoma Drugs Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Hepatocellular Carcinoma Drugs Market Share by Application: 2022 VS 2029

    Figure 8. Hospitals Case Studies

    Figure 9. Clinics Case Studies

    Figure 10. Cancer Rehabilitation Centers Case Studies

    Figure 11. Hepatocellular Carcinoma Drugs Report Years Considered

    Figure 12. Global Hepatocellular Carcinoma Drugs Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 13. Global Hepatocellular Carcinoma Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 14. Global Hepatocellular Carcinoma Drugs Market Share by Region: 2022 VS 2029

    Figure 15. Global Hepatocellular Carcinoma Drugs Market Share by Players in 2022

    Figure 16. Global Top Hepatocellular Carcinoma Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatocellular Carcinoma Drugs as of 2022)

    Figure 17. The Top 10 and 5 Players Market Share by Hepatocellular Carcinoma Drugs Revenue in 2022

    Figure 18. North America Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 19. North America Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)

    Figure 20. United States Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. Canada Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 22. Europe Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Europe Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)

    Figure 24. Germany Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. France Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. U.K. Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Italy Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. Russia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Nordic Countries Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Asia-Pacific Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Asia-Pacific Hepatocellular Carcinoma Drugs Market Share by Region (2018-2029)

    Figure 32. China Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Japan Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. South Korea Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Southeast Asia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. India Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Australia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. Latin America Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Latin America Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)

    Figure 40. Mexico Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Brazil Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Middle East & Africa Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Middle East & Africa Hepatocellular Carcinoma Drugs Market Share by Country (2018-2029)

    Figure 44. Turkey Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Saudi Arabia Hepatocellular Carcinoma Drugs Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Bayer Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 47. Eli Lilly Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 48. Johnson and Johnson Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 49. Pfizer Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 51. Celgene Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 52. F. Hoffmann-la Roche Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 53. Gilead Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 54. GlaxoSmithKline Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 55. Merck Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 56. Novartis Revenue Growth Rate in Hepatocellular Carcinoma Drugs Business (2018-2023)

    Figure 57. Bottom-up and Top-down Approaches for This Report

    Figure 58. Data Triangulation

    Figure 59. Key Executives Interviewed